Compare · LLY vs NRSN
LLY vs NRSN
Side-by-side comparison of Eli Lilly and Company (LLY) and NeuroSense Therapeutics Ltd. (NRSN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NRSN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 45924.3x NRSN ($24.2M).
- LLY has been more active in the news (5 items in the past 4 weeks vs 3 for NRSN).
- LLY has more recent analyst coverage (25 ratings vs 1 for NRSN).
- Company
- Eli Lilly and Company
- NeuroSense Therapeutics Ltd.
- Price
- -
- -
- Market cap
- $1.11T
- $24.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 1
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
Latest NRSN
- NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
- EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
- Chief Executive Officer Ben-Noon Alon bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 6% to 4,534,233 units (SEC Form 4)
- Chief Financial Officer Eisenberg Or bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 20% to 1,504,050 units (SEC Form 4)
- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.